Research a big cost at Biogen Idec
Biogen Idec Inc.’s success with experimental drugs in the late stages of development is costing the company in other areas, driving up research spending and requiring new investments, said Paul Clancy, the company’s chief financial officer.
For more from BostonGlobe.com, sign up or log in below
To continue, please sign up or log in to BostonGlobe.com
Access the full articles and quality reporting of The Boston Globe at BostonGlobe.com
Sign up
Unlimited Access to BostonGlobe.com for 4 weeks for only 99¢.
Are you a Boston Globe home delivery subscriber?
Get FREE access as part of your print subscription.
BostonGlobe.com subscriber
Click to continue reading this article or to log in to BostonGlobe.com.
Waiting for Twitter to feed in the latest...